15.83
1.85 (13.23%)
| Previous Close | 13.98 |
| Open | 14.17 |
| Volume | 3,842,092 |
| Avg. Volume (3M) | 1,058,404 |
| Market Cap | 1,350,275,200 |
| Price / Sales | 124.59 |
| Price / Book | 163.53 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Operating Margin (TTM) | -1,135.42% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 5.00% |
| Total Debt/Equity (MRQ) | 297.04% |
| Current Ratio (MRQ) | 2.93 |
| Operating Cash Flow (TTM) | -99.23 M |
| Levered Free Cash Flow (TTM) | -64.38 M |
| Return on Assets (TTM) | -37.66% |
| Return on Equity (TTM) | -203.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Liquidia Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 65.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Jefferies, 171.64%) | Buy |
| Median | 36.00 (127.42%) | |
| Low | 23.00 (B of A Securities, 45.29%) | Buy |
| Average | 34.80 (119.84%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 22.92 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 15 Aug 2025 | 43.00 (171.64%) | Buy | 25.95 |
| Raymond James | 13 Aug 2025 | 41.00 (159.00%) | Buy | 25.20 |
| Wells Fargo | 13 Aug 2025 | 31.00 (95.83%) | Buy | 25.20 |
| 12 Jun 2025 | 25.00 (57.93%) | Buy | 14.45 | |
| Needham | 12 Aug 2025 | 36.00 (127.42%) | Buy | 24.10 |
| B of A Securities | 11 Jun 2025 | 23.00 (45.29%) | Buy | 14.13 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAIR JASON | - | 28.02 | -26,508 | -728,415 |
| BOYLE DANA | - | 27.68 | -296 | -8,193 |
| KASETA MICHAEL | - | 28.58 | -1,148 | -32,810 |
| KREPP SARAH | - | 27.68 | -209 | -5,785 |
| MANNING PAUL B | - | 27.91 | -670,837 | -18,830,255 |
| MOOMAW SCOTT | - | 28.58 | -70,692 | -2,020,377 |
| SAGGAR RAJEEV | - | 27.46 | -20,000 | -549,200 |
| SCHUNDLER RUSSELL | - | 28.58 | -1,063 | -30,381 |
| SINGH RAMAN | - | 29.22 | -7,500 | -219,150 |
| Aggregate Net Quantity | -798,253 | |||
| Aggregate Net Value ($) | -22,424,566 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 28.13 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SINGH RAMAN | Director | 03 Sep 2025 | Sell (-) | 7,500 | 29.22 | 219,150 |
| ADAIR JASON | Officer | 02 Sep 2025 | Automatic sell (-) | 451 | 28.58 | 12,890 |
| MANNING PAUL B | Director | 02 Sep 2025 | Sell (-) | 328,268 | 28.58 | 9,381,899 |
| KASETA MICHAEL | Officer | 02 Sep 2025 | Automatic sell (-) | 1,148 | 28.58 | 32,810 |
| SCHUNDLER RUSSELL | Officer | 02 Sep 2025 | Automatic sell (-) | 1,063 | 28.58 | 30,381 |
| MOOMAW SCOTT | Officer | 02 Sep 2025 | Automatic sell (-) | 70,692 | 28.58 | 2,020,377 |
| ADAIR JASON | Officer | 29 Aug 2025 | Option execute | 1,562 | - | - |
| MANNING PAUL B | Director | 29 Aug 2025 | Sell (-) | 188,232 | 27.68 | 5,210,262 |
| BOYLE DANA | Officer | 29 Aug 2025 | Automatic sell (-) | 296 | 27.68 | 8,193 |
| KASETA MICHAEL | Officer | 29 Aug 2025 | Option execute | 2,344 | - | - |
| KREPP SARAH | Officer | 29 Aug 2025 | Automatic sell (-) | 209 | 27.68 | 5,785 |
| SCHUNDLER RUSSELL | Officer | 29 Aug 2025 | Option execute | 2,344 | - | - |
| MOOMAW SCOTT | Officer | 29 Aug 2025 | Option execute | 1,875 | - | - |
| SAGGAR RAJEEV | Officer | 28 Aug 2025 | Automatic sell (-) | 20,000 | 27.46 | 549,200 |
| ADAIR JASON | Officer | 28 Aug 2025 | Automatic sell (-) | 26,057 | 27.46 | 715,525 |
| MANNING PAUL B | Director | 28 Aug 2025 | Sell (-) | 154,337 | 27.46 | 4,238,094 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference |
| 12 Aug 2025 | Announcement | Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 05 Aug 2025 | Announcement | Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 |
| 23 Jun 2025 | Announcement | Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |